HSD17B4 is specifically down-regulated in breast and ovarian cancers among various human cancers [21], and this suggests that its silencing is associated with sex hormone metabolism and then sensitivity to trastuzumab. This evidence concerns the gene PLXNA3 and ovarian carcinoma.